Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy ...

Citi initiated coverage of Avidity Biosciences (RNA) with a Buy rating and $70 price target Healthcare policy remains a key biopharma sector ...

BMO Capital initiated coverage of Avidity Biosciences (RNA) with an Outperform rating and $72 price target Avidity’s pipeline includes ...

Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to muscle and heart cells. Learn more on RNA stock here.

Scotiabank began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report issued on Friday morning, ...

NASDAQ RNA opened at $30.04 on Monday. The firm has a market capitalization of $3.61 billion, a P/E ratio of -10.43 and a beta of 1.02. Avidity Biosciences has a 1-year low of $20.80 and a 1-year ...

Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital and ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

Analysts have recently evaluated Avidity Biosciences and provided 12-month price targets. The average target is $69.0, accompanied by a high estimate of $72.00 and a low estimate of $65.00. This ...

BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...

Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 Major milestones ...

On Tuesday, BMO Capital Markets began coverage of Avidity Biosciences (NASDAQ:RNA) shares, assigning an Outperform rating and setting a price target of $72.00. Currently trading at $29.58, the stock ...